File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: ACR appropriateness Criterias ® early-stage non-small-cell lung cancer

TitleACR appropriateness Criterias ® early-stage non-small-cell lung cancer
Authors
KeywordsEarly-stage non-small-cell lung cancer
Medical operability
Surgery
Radiotherapy
Adjuvant
Issue Date2014
Citation
American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, v. 37, n. 2, p. 201-207 How to Cite?
AbstractEarly-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Copyright © 2013 American College of Radiology (ACR).
Persistent Identifierhttp://hdl.handle.net/10722/266983
ISSN
2023 Impact Factor: 1.6
2023 SCImago Journal Rankings: 0.711
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVidetic, Gregory M.M.-
dc.contributor.authorChang, Joe Yujiao-
dc.contributor.authorChetty, Indrin J.-
dc.contributor.authorGinsburg, Mark E.-
dc.contributor.authorKestin, Larry L.-
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorLally, Brian E.-
dc.contributor.authorLoo, Billy W.-
dc.contributor.authorMovsas, Benjamin-
dc.contributor.authorStinchcombe, Thomas E.-
dc.contributor.authorWillers, Henning-
dc.contributor.authorRosenzweig, Kenneth E.-
dc.date.accessioned2019-01-31T07:20:10Z-
dc.date.available2019-01-31T07:20:10Z-
dc.date.issued2014-
dc.identifier.citationAmerican Journal of Clinical Oncology: Cancer Clinical Trials, 2014, v. 37, n. 2, p. 201-207-
dc.identifier.issn0277-3732-
dc.identifier.urihttp://hdl.handle.net/10722/266983-
dc.description.abstractEarly-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Copyright © 2013 American College of Radiology (ACR).-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Clinical Oncology: Cancer Clinical Trials-
dc.subjectEarly-stage non-small-cell lung cancer-
dc.subjectMedical operability-
dc.subjectSurgery-
dc.subjectRadiotherapy-
dc.subjectAdjuvant-
dc.titleACR appropriateness Criterias ® early-stage non-small-cell lung cancer-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1097/COC.0000000000000013-
dc.identifier.pmid25180631-
dc.identifier.scopuseid_2-s2.0-84900399871-
dc.identifier.volume37-
dc.identifier.issue2-
dc.identifier.spage201-
dc.identifier.epage207-
dc.identifier.eissn1537-453X-
dc.identifier.isiWOS:000333713100019-
dc.identifier.issnl0277-3732-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats